Firstkind Ltd
Firstkind Ltd, a subsidiary of Sky Medical Technology Ltd, is a UK-based medical devices company. Through its innovative mechanism of neuromuscular electrostimulation, Firstkind has developed a non-invasive, ground-breaking technology platform, OnPulse, embedded in its industry-leading brand, the geko device. Our range of non-invasive geko™ products are wearable therapy devices tailored to different medical applications, selling both direct and through partnerships and distributors in each clinical area. Clinical areas of interest include the prevention of venous thromboembolism (VTE), the prevention and reduction of oedema and wound healing. Firstkind is committed to providing quality customer service. In order to guarantee this we have built a global network of distributor partners who have the resources and knowledge to market and sell geko™ products and services locally.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
About Us
Partnership makes us who we are. We are committed to partnering with healthcare professionals to solve challenging medical problems. Through local partnerships we work with clinicians to overcome challenges that are recognised worldwide. Together we identify clinical needs and translate these into cutting-edge products and evidence-based therapies to simplify treatments for clinicians and improve patient outcomes.
Our vision is to drive innovation through collaborative partnerships to solve challenging medical problems. To create an innovation-driven, patient-focused company capable of achieving sustainable top-tier performance through outstanding execution and a consistent stream of evidence-based therapies that provide compelling patient benefits, differentiated clinical performance and economic value.
- Integrity
- Innovation
- Collaboration
- Accountability
- Respect
Company Profile
The geko™ device – providing increased blood flow for better patient outcomes
Population ageing, lengthening life spans, and the rising prevalence of obesity and other chronic conditions are increasing the demand for vascular health solutions. Globally more than 20 million people annually suffer from strokes, post-surgical swelling, and non-healing wounds that are not being adequately treated by current therapies and are at further risk of medical complications – and poor circulation can be related to many of the diseases and conditions these patients suffer1.
Our mission is to provide clinicians with an innovative solution that addresses poor circulation and delivers safe recovery and accelerated healing. We have developed and commercialized a bioelectronic nerve stimulation technology, clinically proven to increase blood circulation2. The award-winning geko™ device, uses the body’s own internal compression system (specific nerves and muscles) to provide a significant increase in blood circulation on-demand, in the hospital or at home.
External compression, multi-layer bandages, and drugs are currently the standard of care for increasing blood circulation but do not work for all conditions. Existing intermittent pneumatic compression device (IPC) and stockings have poor compliance, multi-layer bandaging can be difficult to apply and drugs can cause an unpredictable bleed risk3,4. The geko™ device overcomes these challenges and is uniquely positioned to address significant unmet need when drug and current compression devices are impractical or contraindicated5,6.
The size of a wrist-watch and worn at the knee, the battery-powered geko™ device gently stimulates the common peroneal nerve with painless electrical pulses, activating the calf and foot muscle pumps, increasing blood flow in the deep veins of the calf at a rate equal to 60%2 of walking, without a patient having to move.
The device provides safer and faster recovery by reducing post-surgical complications and accelerated healing. It does this by (1) eliminating post-operative swelling e.g. after knee, hip, or foot & ankle surgery7 (2) reducing the risk of deadly blood clots e.g. in stroke patients5, (3) accelerating the healing of wounds8 e.g. in people with poor blood circulation.
The clinical effectiveness of the geko™ device has been demonstrated through randomised controlled trials and real-world studies. These studies have helped us to achieve regulatory approval in many countries, including the US (510k clearances), Europe, the Middle East and Asia, with the result that key opinion leaders are now actively using and recommending the geko™ device, moving geko™ from early adoption to repeat use in key references centres in 14 target countries, with a focus in three analogous medical pathways:
- Orthopaedic – studies show the geko™ device reduces swelling and pain post-operatively7 and accelerates readiness for surgery when surgery is prevented by excessive pre-operative swelling6.
- Venous thromboembolism (VTE) – complications caused by VTE are significant in patients suffering acute stroke. The geko™ device provides preventive circulation therapy to all at-risk hospital patients9.
- Wound care – the geko™ device delivers markedly increased blood flow to heal complex wounds10.